Aspect Biosystems, a UBC spinoff that 3D prints live tissue implants intended to cure diabetes and liver ailments is featured in the Globe and Mail for a development deal it has struck with Danish drug giant, Novo Nordisk that could be worth more than $2.6 billion USD.
Aspect Biosystems was created in 2014 around research led by Dr. Konrad Walus. The company combines microfluidics and 3D bioprinting to create living, human tissues in order to fuel medical research and the development of bioprinted therapeutics that will save lives and make people healthier.